Category stocks

Astrazeneca Q2 Earnings Call Highlights

Key Points - Solid first-half performance: AstraZeneca reported revenue growth of 6% at constant exchange rates and 11% excluding generic-competition effects, while core EPS rose 11%. The company maintained its full-year outlook and reaffirmed its goal of reaching $80 bill